Mallikarjuna Mukka, MD
Infectious Disease · Fort Worth, TXNPI 1487608923
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Dexcom, Inc. at 22.7% of the total.
Across 7 payments — averaging $94.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$150
- Merck$116
- Paratek Pharmaceuticals, Inc.$116
- Insmed, Inc.$111
- AbbVie$108
- Mimedx Group, Inc.$39
- plus $21 from 1 others
What the payments were for
- Food & beverage$64097%
- Education$213%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 1 | $150 |
| Merck | 1 | $116 |
| Paratek Pharmaceuticals, Inc. | 1 | $116 |
| Insmed, Inc. | 1 | $111 |
| AbbVie | 1 | $108 |
| Mimedx Group, Inc. | 1 | $39 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$150
- DEXCOM STELO GLUCOSE BIOSENSOR$150
- RECARBRIO$116
- NUZYRA$116
- Arikayce$111
- DALVANCE$108
How this compares
$660 in reported general payments places this provider in the 55th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $60,003 |
| ErtapenemErtapenem Sodium | 37 | $14,245 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 34 | $5,743 |
| Cefepime Hcl | 28 | $5,627 |
| Daptomycin | 18 | $4,411 |
| Meropenem | 22 | $4,096 |
| Vancomycin Hcl | 30 | $4,061 |
| CeftriaxoneCeftriaxone Sodium | 31 | $1,736 |
| Cefazolin Sodium | 17 | $939 |
| Rifampin | 21 | $768 |
| NitrofurantoinNitrofurantoin Macrocrystal | 17 | $470 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 40 | $418 |
| Doxycycline Hyclate | 18 | $315 |
| Ethambutol Hcl | 11 | $275 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Fort Worth
- Cedric SpakFort Worth$427K
- Cheryl McDonaldFort Worth$179K
- Daniel BarbaroFort Worth$44K
- Elizabeth RaceDallas$1.5M
- Ogechika AlozieEl Paso$834K
- Joseph GatheHouston$695K
- Roy ChemalyHouston$686K
- Ben BarnettHouston$424K
- Uriel SandkovskyDallas$320K
- Amar SafdarHouston$284K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.